XML 35 R25.htm IDEA: XBRL DOCUMENT v3.22.0.1

Restructuring, Impairment, and Related Charges (Tables)

9 Months Ended

Dec. 31, 2021

Restructuring and Related Activities [Abstract]

Restructuring, Impairment, and Related Costs

Restructuring, impairment, and related charges during the three and nine months ended December 31, 2021 consisted of the following:

			Three Months Ended December 31, 2021
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International						Corporate						Total
Severance and employee-related costs, net			$	—					$	—					$	—					$	—					$	1					$	1
Exit and other-related costs (1)			3						—						1						6						6						16
Asset impairments and accelerated depreciation			—						—						—						(1)						2						1
Total			$	3					$	—					$	1					$	5					$	9					$	18

(1)Exit and other-related costs primarily consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

			Nine Months Ended December 31, 2021
(In millions)			U.S. Pharmaceutical (1)						Prescription Technology Solutions (1)						Medical-Surgical Solutions (1)						International (2)						Corporate (1)						Total
Severance and employee-related costs, net			$	2					$	(1)					$	1					$	10					$	2					$	14
Exit and other-related costs (3)			7						2						3						21						33						66
Asset impairments and accelerated depreciation			16						17						5						35						55						128
Total			$	25					$	18					$	9					$	66					$	90					$	208

(1)Costs primarily relate to the transition to the partial remote work model described above.

(2)Primarily represents costs related to optimization programs in Canada as well as the transition to a partial remote work model and the U.K. operating model and cost optimization efforts both described above.

(3)Exit and other-related costs primarily consist of accruals for costs to be incurred without future economic benefits, project consulting fees, and other exit costs expensed as incurred.

Restructuring, impairment, and related charges during the three and nine months ended December 31, 2020 consisted of the following:

			Three Months Ended December 31, 2020
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International (1)						Corporate (2)						Total
Severance and employee-related costs, net			$	3					$	—					$	(3)					$	2					$	7					$	9
Exit and other-related costs (3)			3						—						1						5						6						15
Asset impairments and accelerated depreciation			—						—						—						9						7						16
Total			$	6					$	—					$	(2)					$	16					$	20					$	40

(1)Primarily represents costs associated with the U.K. operating model and cost optimization efforts described above.

(2)Primarily represents costs associated with an operating model and cost optimization initiative and with the relocation of the Company’s corporate headquarters. Both of these initiatives were substantially completed in the year ended March 31, 2021.

(3)Exit and other-related costs primarily include project consulting fees.

			Nine Months Ended December 31, 2020
(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International (1)						Corporate (2)						Total
Severance and employee-related costs, net			$	10					$	—					$	—					$	22					$	31					$	63
Exit and other-related costs (3)			8						—						3						12						20						43
Asset impairments and accelerated depreciation			—						—						1						40						9						50
Total			$	18					$	—					$	4					$	74					$	60					$	156

(1)Primarily represents costs associated with the U.K. operating model and cost optimization efforts described above, and an operating model and cost optimization initiative which was substantially completed in the year ended March 31, 2021.

(2)Primarily represents costs associated with an operating model and cost optimization initiative and with the relocation of the Company’s corporate headquarters. Both of these initiatives were substantially completed in the year ended March 31, 2021.

(3)Exit and other-related costs primarily include project consulting fees.

Schedule of Restructuring and Asset Impairment Charges

The following table summarizes the activity related to the restructuring liabilities associated with the Company’s restructuring initiatives for the nine months ended December 31, 2021:

(In millions)			U.S. Pharmaceutical						Prescription Technology Solutions						Medical-Surgical Solutions						International						Corporate						Total
Balance, March 31, 2021 (1)			$	19					$	4					$	3					$	66					$	59					$	151
Restructuring, impairment, and related charges			25						18						9						66						90						208
Non-cash charges			(16)						(17)						(5)						(35)						(55)						(128)
Cash payments			(15)						(1)						(5)						(22)						(26)						(69)
Other			—						—						—						(11)						(7)						(18)
Balance, December 31, 2021 (2)			$	13					$	4					$	2					$	64					$	61					$	144

(1)As of March 31, 2021, the total reserve balance was $151 million, of which $99 million was recorded in “Other accrued liabilities” and $52 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.

(2)As of December 31, 2021, the total reserve balance was $144 million, of which $52 million was recorded in “Other accrued liabilities,” $44 million was recorded in “Liabilities held for sale,” and $48 million was recorded in “Other non-current liabilities” in the Condensed Consolidated Balance Sheet.

X

- References

No definition available.

+ Details

Name:	us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 5.P.3)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 5.P.4)
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 420
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.P.4(b)(2))
-URI http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747

+ Details

Name:	us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration